Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance Pharmaceutical Investing
Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial Life Science Investing
BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States Pharmaceutical Investing
Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022 Pharmaceutical Investing
Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel Pharmaceutical Investing
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder Company News
Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough Pharmaceutical Investing
